March 11, 2022 saw the first face-to-face exchange fair of medical enterprises in Xiamen, which drew the attention of nearly 200 participants from 88 enterprises and 19 medical institutions, representing the high emphasis of Xiamen on the development of the biomedical industry. The biomedicine and healthcare industry is a hundred-billion-worth industrial chain (cluster) under the intensive cultivation and support of Xiamen, and one of the most technologically innovative and aggressively growing strategic emerging industries. In 2019, Xiamen successfully made the list of first national strategic emerging industrial clusters. In 2021, Xiamen ranked the 15th in the "Leaderboard of National Biomedicine Industrial Parks in Comprehensive Competitiveness", and the 3rd in the "medical apparatus and instruments" section. Due to the increasing innovation capability of enterprises in recent years, a torrent of well-known biomedical enterprises have kept emerging, such as Wantai Biopharm, AmoyDx, Amoytop Biotech, and Double Medical. Xiamen also boasts the world's first hepatitis E vaccine, the first nerve growth factor officially approved for clinical purpose, China's first cervical cancer vaccine, the first PEG-IFN with independent intellectual property, the first tumor drug companion diagnostic product, and other innovative products.